CD4+ T cells, cytokine release (anti-CD3/anti-CD28 stimulation)| Type of assay | Th17 polarity - Cytokines | | Biological model | CD4+ T cells | | Species | Human | | Endpoint | IL-17 release, or other Th17 cytokines |
| CD4TL-0007 | T lymphocytes: anti-inflammatory effects/immunosuppression, Psoriasis, Psoriasis, T lymphocytes: anti-inflammatory effects/immunosuppression - cell-mediated and humoral immunity modulation | Th17 polarity - Cytokines | CD4+ T cells | Human | IL-17 release, or other Th17 cytokines | ELISA / EIA | Anti-CD3 / Anti-CD28 | |
RHE, gene expression + histology (OSM stimulation)| Type of assay | Gene expression | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | mRNA: e.g. S100A7, KRT10 + histology |
| EPIBA-0005 | Psoriasis, Psoriasis | Gene expression | Reconstructed Epidermis, BIOalternatives RHE | Human | mRNA: e.g. S100A7, KRT10 + histology | RT-qPCR + HE staining | OSM | |
RHE, gene expression (cytokine stimulation)| Type of assay | Gene expression | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 |
| EPIBA-0006 | Psoriasis, Psoriasis | Gene expression | Reconstructed Epidermis, BIOalternatives RHE | Human | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 | RT-qPCR, qPCRarray (standard or customized) | IL-17 / OSM / TNF- alpha | |
RHE, gene expression + histology (cytokine stimulation)| Type of assay | Gene expression | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | Specific mRNA(s) + histology, mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 |
| EPIBA-0007 | Psoriasis, Psoriasis | Gene expression | Reconstructed Epidermis, BIOalternatives RHE | Human | Specific mRNA(s) + histology, mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 | RT-qPCR + HE staining, qPCRarray (standard or customized) + HE staining | IL-17 / OSM / TNF- alpha | |
RHE, gene expression (T cell medium stimulation)| Type of assay | Gene expression | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 |
| EPIBA-0008 | Psoriasis, Psoriasis | Gene expression | Reconstructed Epidermis, BIOalternatives RHE | Human | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 | RT-qPCR, qPCRarray (standard or customized) | Psoriatic T cell medium | |
RHE, gene expression + histology (T cell medium stimulation)| Type of assay | Gene expression | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | Specific mRNA(s) + histology, mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 |
| EPIBA-0009 | Psoriasis, Psoriasis | Gene expression | Reconstructed Epidermis, BIOalternatives RHE | Human | Specific mRNA(s) + histology, mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 | RT-qPCR + HE staining, qPCRarray (standard or customized) + HE staining | Psoriatic T cell medium | |
RHE, skin innate immunity markers expression (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | Expression of e.g. S100A7, beta-defensin 2/4, RNAse7 |
| EPIBA-0057 | Psoriasis, Psoriasis | Protein markers | Reconstructed Epidermis, BIOalternatives RHE | Human | Expression of e.g. S100A7, beta-defensin 2/4, RNAse7 | Immunohistofluorescence or IHC | IL-17 / OSM / TNF- alpha | |
RHE, IL-8 release (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Reconstructed Epidermis, BIOalternatives RHE | | Species | Human | | Endpoint | IL-8 release |
| EPIBA-0058 | Psoriasis, Psoriasis | Protein markers | Reconstructed Epidermis, BIOalternatives RHE | Human | IL-8 release | ELISA / EIA | IL-17 / OSM / TNF- alpha | |
NHEK, gene expression (cytokine stimulation)| Type of assay | Gene expression | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 |
| NHEK-0007 | Psoriasis, Psoriasis | Gene expression | Epidermal keratinocytes (NHEK) | Human | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 | RT-qPCR, qPCRarray (standard or customized) | IL-17 / OSM / TNF- alpha | |
NHEK, gene expression (T cell medium stimulation)| Type of assay | Gene expression | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 |
| NHEK-0008 | Psoriasis, Psoriasis | Gene expression | Epidermal keratinocytes (NHEK) | Human | mRNA: e.g. DEFB4, S100A7, CXCL8, KRT10,..., mQPA-NHEK-PSO-16, mQPA-NHEK-PSO-32, mQPA-NHEK-PSO-64 | RT-qPCR, qPCRarray (standard or customized) | Psoriatic T cell medium | |
NHEK, antimicrobial peptide release (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | beta-defensin 2/4 release, Elafin release |
| NHEK-0009 | Psoriasis, Psoriasis | Protein markers | Epidermal keratinocytes (NHEK) | Human | beta-defensin 2/4 release, Elafin release | ELISA / EIA | IL-17 / OSM / TNF- alpha | |
NHEK, chemokine release (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | IL-8 release, CXCL-1 release |
| NHEK-0010 | Psoriasis, Psoriasis | Protein markers | Epidermal keratinocytes (NHEK) | Human | IL-8 release, CXCL-1 release | ELISA / EIA | IL-17 / OSM / TNF- alpha | |
NHEK, S100A7 expression (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | S100A7 immunolabeling |
| NHEK-0011 | Psoriasis, Psoriasis | Protein markers | Epidermal keratinocytes (NHEK) | Human | S100A7 immunolabeling | Immunofluorescence | IL-17 / OSM / TNF- alpha | |
NHEK, cytokeratin 10 expression (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | Cytokeratin 10 immunolabeling |
| NHEK-0012 | Psoriasis, Psoriasis | Protein markers | Epidermal keratinocytes (NHEK) | Human | Cytokeratin 10 immunolabeling | Immunofluorescence | IL-17 / OSM / TNF- alpha | |
NHEK, 4 selected protein expression (cytokine stimulation)| Type of assay | Protein markers | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | beta-defensin, IL-8, S100A7, KRT10 |
| NHEK-0013 | Psoriasis, Psoriasis | Protein markers | Epidermal keratinocytes (NHEK) | Human | beta-defensin, IL-8, S100A7, KRT10 | Immunofluorescence + ELISA | IL-17 / OSM / TNF- alpha | |
NHEK, NF kappaB translocation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | NF kappaB translocation |
| NHEK-0014 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | NF kappaB translocation | Immunofluorescence | IL-17 / OSM / TNF- alpha | |
NHEK, NF kappaB translocation (TNF- alpha stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | NF kappaB translocation |
| NHEK-0015 | Psoriasis, Atopic dermatitis, Psoriasis, Atopic dermatitis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | NF kappaB translocation | Immunofluorescence | TNF- alpha | |
NHEK, STAT1 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT1 phosphorylation |
| NHEK-0016 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT1 phosphorylation | Western blot | IL-17 / OSM / TNF- alpha | |
NHEK, STAT1 activation (OSM stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT1 phosphorylation |
| NHEK-0017 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT1 phosphorylation | Western blot | Oncostatin M | |
NHEK, STAT1 activation (cytokine stimulation)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | STAT1 phosphorylation |
| NHEK-0018 | Psoriasis, Psoriasis | Signal transduction | Epidermal keratinocytes (NHEK) | Human | STAT1 phosphorylation | Flow cytometry (CBA) | IL-17 / OSM / TNF- alpha | |
